Assessment
Questionnaire

Have a symptom?
See what questions
a doctor would ask.
 
News » Celecoxib no longer allowed to be used as a cancer treatment
 

Celecoxib no longer allowed to be used as a cancer treatment

The NIH has stopped the use of celecoxib a Cox-2 inhibitor as a cancer treatment after the Data Safety and Monitoring Board reported a 2 and a half time increase in risk of cardiovascular events.

Source: summary of medical news story as reported by New Kerala

Related Disease Topics:

Article Source Details

About: Celecoxib no longer allowed to be used as a cancer treatment

Date: 18 December 2004

Source: New Kerala

URL: http://www.newkerala.com/news-daily/news/features.php?action=fullnews&id=48677

Related Medical Topics

This summary article refers to the following medical categories:

More News Topics

  • Ecstasy overuse medically unsafe
  • Eczema asthma link
  • Eczema may be a sign of other allergic conditions
  • Effect of depression amplifies through generations
  • Effects of stroke decreased with antioxidants
  • Efficacy study compares two drug treatment for GERD
  • Elderly depression and insomnia
  • Elderly depression needs to be prioritised
  • Elderly diet supplement carries unknown risks
  • Elderly face high suicide risk
  • Elderly man's quality of life drastically reduced due to a misdiagnosis that continued for 13 years.
  • Elderly woman dies after her medicine dosage was quadrupled
  • Elderly woman suffers pain of two undiagnosed broken legs for four days
  •  

    By using this site you agree to our Terms of Use. Information provided on this site is for informational purposes only; it is not intended as a substitute for advice from your own medical team. The information on this site is not to be used for diagnosing or treating any health concerns you may have - please contact your physician or health care professional for all your medical needs. Please see our Terms of Use.

    Home | Symptoms | Diseases | Diagnosis | Videos | Tools | Forum | About Us | Terms of Use | Privacy Policy | Site Map | Advertise